To overcome these limitations, we embarked on developing software that enables the complete process of 3D vascular reconstruction and simulation using purely domestic technology.

After countless sleepless nights of coding and refining algorithms, we finally completed our own software.

However, we soon faced an even greater challenge.
We realized that the results of our completed computer simulation were not suitable for use in clinical settings.

This was because various artificial factors intervened in the simulation process, making it difficult to accurately reflect the actual condition of the patient.

Despite having spent years developing the software, we made a bold decision.
We decided to abandon the existing approach and explore an entirely new method.

"If it is not the best solution for patients, we must boldly abandon it and start over from scratch."

This decision was not an easy one.
However, our goal was not just to develop software, but to create a tool that would make a real difference in saving patients' lives.

The journey to find a new approach was a continuous cycle of trial and error.

Whenever an idea emerged, we immediately contacted the developers for programming and analyzed the resulting data—repeating this process more than 200 times.

And finally, we made a groundbreaking discovery.
We discovered that by utilizing hidden characteristics in TOF-MRA images, we could calculate blood force (Signal Intensity Gradient).
This was a groundbreaking method that allowed for the precise measurement of vascular wall shear stress using only TOF-MRA images, which can be captured in just four minutes—eliminating the need for complex conventional techniques.

"In a country that does not manufacture MR devices, gaining recognition for new MR technology was nearly impossible."

Even after developing the Signal Intensity Gradient (SIG) technology, the barriers remained high.
Every time we submitted a paper to an international journal, our MR-related technology faced skepticism simply because it was developed in Korea, a non-MR-manufacturing country.

However, we did not give up. We continued to collect more data, conducted even more rigorous validations, and enhanced the quality of our research papers.
As a result, our research gradually gained international recognition, and today, the effectiveness of our Signal Intensity Gradient (SIG) technology is being validated through multiple SCI(E) papers.

The true value of our technology was proven in clinical practice.

Research on cerebrovascular hemodynamic changes using our Signal Intensity Gradient (SIG) technology is actively being conducted at seven major university hospitals across the country, including Seoul National University Hospital. Clinicians are recognizing its practical value and effectiveness.

It is through this relentless journey of challenge and innovation that VINT (Visual INTelligence) was born.

VINT is the world's first blood force measurement tool to receive medical device approval (Certification No. 23-4077) from the Korean Ministry of Food and Drug Safety (MFDS) in January 2023.

Protected by seven patents, this groundbreaking technology is opening a new horizon in the diagnosis of cerebrovascular diseases.

MediImage aims to introduce a new paradigm in cerebrovascular disease diagnosis through VINT.

Our goal is to make blood force (SIG) data analysis a standard practice in clinical settings after MRA scans and to establish VINT as an essential diagnostic tool for cerebrovascular assessment.

MediImage will continue its relentless research and innovation to save patients' lives and provide healthcare professionals with better diagnostic tools.

"MediImg will drive innovation that turns the impossible into reality."